Medicine Recommendations

Non-radiographic axial spondyloarthritis (NICE TA497)

NICE TA497 - Golimumab for treating non-radiographic axial spondyloarthritis

ADHD in children and adolescents aged 6 to 17 years for whom stimulants are not suitable, not tolerated or have been shown to be ineffective

Guselkumab for treating moderate to severe plaque psoriasis (NICE TA521)

Administration in patients with respiratory conditions

Schizophrenia and other psychoses, mania, anxiety

Maintenance in schizophrenia and other psychoses

Rapid Tranquilisation

All licensed indications

Gender Dysphoria

Osteoarthritis

Psoriasis

Acute Gout (as per LSCMMG Guidelines)

For replacement therapy of adrenal insufficiency in children and adolescents (from birth to <18 years old)

Treatment of adrenal insufficiency in adults.

Treatment of essential thrombocythemia or polycythaemia vera with a high risk for thromboembolic complications

Psoriasis

The prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults suffering from symptomatic Sickle Cell Syndrome

Rheumatoid conditions, lupus erythematosus, dermatological conditions

Hypersalivation

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of post menopausal osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures